A practitioner-supervised botanical and peptide protocol supporting antimicrobial defense, immune modulation, neuroinflammation, and antioxidant restoration in complex chronic infections.
✓Provides the most in vitro-active botanical against stationary phase Borrelia burgdorferi - Cryptolepis sanguinolenta, the top-performing herb in the Johns Hopkins 2020 botanical screening study
✓Supports activity against multiple infection phases including Babesia co-infections with liposomal Artemisinin, offering 4-5x higher bioavailability than standard artemisinin
✓Supports immune modulation and anti-TNF-alpha activity with Cat's Claw V-Max, shown in vitro to enhance CD57 natural killer cell populations commonly depleted in chronic tick-borne illness
✓Supports neuroinflammation recovery and gut-immune axis integrity with BPC-157 + KPV - peptides increasingly used in functional medicine Lyme protocols
$440 $374 Save $66 (15%)
Most supplement protocols for Lyme disease and chronic tick-borne infections miss two critical features: coverage of the stationary phase 'persister' bacteria that standard antibiotics cannot eradicate, and support for the secondary damage - neuroinflammation, gut barrier compromise, antioxidant depletion - that chronic infection creates. This protocol addresses both layers.
🔒 Physician-Formulated | ✓ Third-Party Tested | ★ Ojus Quality Guarantee
Lyme & Chronic Infection Protocol
The botanical combination addresses Borrelia at multiple vulnerability windows. Cryptolepis targets both actively dividing log-phase bacteria and dormant stationary phase cells (including biofilm microcolonies) through cryptolepine's DNA intercalation mechanism - the only botanical in the Feng et al.

